1. Introduction {#s0005}
===============

Ameliorating psychotic symptoms has been a traditional target in the treatment of schizophrenia. However, this approach has been reported to only partially improve functional outcomes of patients in real-world settings ([@bb0025], [@bb0030]). Consequently, efforts have been made to develop therapeutics for disturbances of cognitive function, e.g. several types of memory, executive function, attention, and verbal fluency, which has been shown to predict social outcomes more closely than do psychotic symptoms ([@bb0040], [@bb0165]). The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) ([@bb0100]) and the Brief Assessment of Cognitive Function in Schizophrenia (BACS) ([@bb0060]) represent assessment tools to evaluate such neurocognitive functioning.

As a level of functional outcome mediating cognitive function (primary measure) and social function, scales to assess functional capacity (for daily living activities), or *co-primary measures*, have been implemented ([@bb0035]). The UCSD Performance-based Skills Assessment-Brief (UPSA-B) ([@bb0085]) is one of such measures broadly used to evaluate everyday functioning. This scale represents a performance-based scale of everyday functioning, whose Japanese version has been developed and validated ([@bb0155], [@bb0150]).

For the assessment of social function, attempts have been made to determine which tools can adequately measure "real-world functional outcomes" linked to neurocognition and daily activity skills ([@bb0045], [@bb0070]). Accordingly, the Validation of Everyday Real-World Outcomes (VALERO) initiative supported by the Rand expert panel selected the Quality of Life Scale (QLS), Social Functioning Scale (SFS), Specific Levels of Functioning Scale (SLOF), Social Behavior Schedule, Independent Living Skills Schedule, and Life Skills Profile as appropriate measures of social, residential, and vocational outcomes ([@bb0070]). Specifically, [@bb0045] found the SLOF, among other social function scales discussed by the RAND panelists, best predicts performances on the MCCB, UPSA-B, and the advanced finances subscale of the Everyday Functioning Battery.

The SLOF has been developed as an interview-based multidimensional assessment measure of social outcomes, including interpersonal, vocational and independent-living domains ([@bb0125]). To accommodate cross-cultural adaptability of functional outcome measures, its original (English language) version has been translated into other languages for international use, e.g. ([@bb0090]). Although we have developed and validated Japanese versions of the SFS Individuals\' version modified for the MATRICS-PASS (SFS-PASS) ([@bb0145]), the development and validation of the SLOF Japanese version has been awaited, in line with the growing interest in global clinical trials.

Impairment of metacognition, or the ability to think about thinking, has been suggested to be associated with some functional outcomes, e.g. cognitive function (neuropsychological performance) ([@bb0080]), functional capacity (everyday functioning) as measured by the UPSA ([@bb0075]), and quality of life as measured by the QLS ([@bb0080]) in patients with schizophrenia. Among the domains of metacognition, cognitive insight has been conceptualized as the mental processes involved in self re-evaluation of anomalous experiences and specific misinterpretations ([@bb0005]). In this respect, the Beck Cognitive Insight Scale (BCIS) ([@bb0005]) has been developed to evaluate self-reflectiveness and self-certainty in individuals with psychiatric conditions. The Japanese version of the BCIS was developed based on the original version, and its validity has been confirmed in patients with schizophrenia ([@bb0160]).

Although the lack of *clinical* insight (awareness of the illness), a core feature of schizophrenia, has been suggested to influence outcome ([@bb0015]), limited information is available about whether *cognitive* insight is related to real-world outcomes in schizophrenia. It was hypothesized that cognitive insight would be associated with social function, particularly when assessed with objective (interview-based) measures, such as the SLOF, but not subjective (self-reported) measures, such as the SFS. Therefore, the present study was conducted to determine convergent validity of the Japanese version of the SLOF, and if cognitive insight would be related to social function, as measured by the SLOF.

2. Methods {#s0010}
==========

2.1. Subjects {#s0015}
-------------

This was a multi-center collaborative study, whose design, characteristics of participants and other information have been registered (UMIN ID: 000,012,671). Fifty-eight Japanese patients with schizophrenia were recruited at 10 participating institutions throughout Japan, i.e. Hokkaido University, Keio University, Tokyo Women\'s Medical University, Showa University, Nara Medical University, Kansai University, Oita University, University of Occupational and Environmental Health, Hizen Psychiatric Center, and National Center of Neurology and Psychiatry. Diagnosis was made based on DSM-IV-TR criteria by experienced psychiatrists using all available information. Patients known to be abusing alcohol or illicit drugs, or those with epilepsy, brain damage, or neurologic disorders were excluded.

Demographic data of these subjects are presented in [Table 1](#t0005){ref-type="table"}. Approximately half of them were female. All patients were taking antipsychotic drugs. Written informed consent was obtained from all participants. The study protocol was approved by the ethics committees of participating institutions.Table 1Demographic data.Table 1Mean (SD)RangeM/F31/27Age, yr35.9 (9.6)20--58Duration, month148.3 (111.4)4--396PANSS61.1 (20.1)33--115Estimated IQ100.2 (11.8)69.3--119.8Medication (CPZ equiv. mg/day)546.8 (407.7)5--1730BACS (z-score in SD unit)−2.0 (2.2)−8.6 to 2.6UPSA-B72.4 (18.8)0--94SFS109.4 (26.4)17--186SLOF90.7 (15.7)42--117BCIS8.5 (5.4)−2 to 24

2.2. Assessment procedures {#s0020}
--------------------------

Before the study was started, all raters received extensive training in performing the assessments, according to the procedure previously reported ([@bb0130]).

### 2.2.1. Social function measures {#s0025}

#### 2.2.1.1. SLOF {#s0030}

In this study, the abbreviated version of the SLOF, consisting of the following domains, was used, according to the recent literature ([@bb0015], [@bb0115], [@bb0120], [@bb0130]); *Interpersonal Functioning* (e.g., initiating, accepting and maintaining social contacts; effectively communicating), independent participation in *Everyday Activities* (shopping, using telephone, paying bills, use of leisure time, use of public transportation), and *Vocational Functioning* (e.g., employable skills, level of supervision required to complete tasks, ability to stay on task, completes tasks, punctuality). For the purpose of this study, we examined only summary scores based on these three domains, as previously reported ([@bb0115]). Some of the subscales of the SLOF, e.g. the social acceptability and personal care subscales, were not included in calculation of the total score, based on the suggestions by the Rand Panel, as described in previous studies ([@bb0015], [@bb0115], [@bb0130]).

The raters conducted the interviews with ratings generated by the patient and informant; interviewer-rated scores of the SLOF was used as an objective measure of social function ([@bb0115], [@bb0130]).

The SLOF Japanese version ([@bb0135]) was developed based on the original version. The translated version has been approved by developers after conducting independent forward and back translations, reconciliation, and pilot testing on patients.

#### 2.2.1.2. SFS {#s0035}

The SFS-PASS was used to evaluate overall social functioning. This scale was designed by the MATRICS-Psychometric and Standardization Study (MATRICS-PASS) ([@bb0065], [@bb0105]) for the validation study of the MCCB. It comprises the Social Functioning Scale Individuals\' version ([@bb0010], [@bb0095]). The SFS-PASS, consisting of 7 domains, assesses social competence by asking subjects\' status or activities. Data were collected from the participants\' self-rating/reports. To enhance the accuracy of self-rating, most items were accompanied by anchor points (frequencies). For example, the degree of activities of 'Visiting friends' is well defined as 'Never' = 0 times \[0 point\]; Rarely = more than once in recent 3 months \[1\]; Sometimes = more than once in a month \[2\]; Often = more than once in a week \[3\]. The associations between ratings with this Japanese version of the SFS (self-reported) and the MCCB composite score have been reported ([@bb0145], [@bb0140]).

### 2.2.2. Functional capacity measure {#s0040}

#### 2.2.2.1. UPSA-B {#s0045}

The Japanese version of the UPSA-B ([@bb0085]) was used to assess everyday functioning. This battery consists of Finances and Communication subdomains. The former includes basic financial skills such as counting change or extracting information from a bill payment. The latter evaluates communicative ability such as speaking on the phone or rescheduling an appointment. All the tasks are role-played. Each task score is summed by subscales and then transformed to standard scores (0--50). The total score is the sum of the subscale standard scores (0--100). The Japanese version was developed based on the international version of the UPSA-B, with some modifications to adjust for differences in everyday living skills in Japan ([@bb0150]). The equivalency to its original version and validity have been confirmed ([@bb0155]).

### 2.2.3. Neurocognition {#s0050}

#### 2.2.3.1. Brief Assessment of Cognition in Schizophrenia (BACS) {#s0055}

Cognitive assessment was conducted by the Japanese version of the Brief Assessment of Cognition in Schizophrenia (BACS) ([@bb0050]), based on the original version ([@bb0060]). The cognitive domains included in the BACS are verbal memory, working memory, motor speed, verbal fluency, attention, and executive function. The primary measure from each test of the BACS was standardized by creating z-scores whereby the mean score of Japanese healthy controls was set to zero and the standard deviation set to one ([@bb0050]). A composite score was calculated by averaging all z-scores of the six primary measures.

### 2.2.4. Cognitive insight {#s0060}

Cognitive insight (metacognition) was measured by the BCIS Japanese version ([@bb0160]). It is a self-report instrument consisting of 15 items rated on a 4-point scale (0, do not agree at all; to 3, agree completely).

### 2.2.5. Psychopathology {#s0065}

The severity of symptoms was measured by the Positive and Negative Syndrome Scale (PANSS) Japanese version ([@bb0055]).

### 2.2.6. Statistical analyses {#s0070}

SPSS ver. 22.0 was used for statistical analyses. Test--retest reliability of the SLOF scores was examined by Kendall\'s rank correlation coefficient. The internal consistency of the SLOF were measured by Cronbach alpha coefficients. Pearson\'s correlation coefficients with scores of the SFS, BACS, and UPSA-B were obtained to test the validity of the SLOF. Also, the relationships between summary scores of the SLOF and those of the BCIS or PANSS were evaluated by the Pearson\'s method. Significance was considered when p-value was less than 0.05.

3. Results {#s0075}
==========

3.1. Demographic data {#s0080}
---------------------

[Table 1](#t0005){ref-type="table"} shows demographic backgrounds of patients. All were medicated. Generally, they were relatively chronic, with mean duration of illness \>12 yr. Psychometric variables were normally distributed. Mean (SD) of SLOF subscale scores were: *Interpersonal Functioning*, 21.8 (6.0); *Everyday Activities,* 48.1 (7.1); and *Vocational Functioning,* 20.8 (5.5).

3.2. Reliability {#s0085}
----------------

Cronbach alpha for the SLOF Japanese version was 0.80.

3.3. Validity {#s0090}
-------------

As shown in [Table 2](#t0010){ref-type="table"}, significant positive correlations were observed between scores on the SLOF and those of the SFS, BACS, UPSA-B, and BCIS. Also, SLOF scores were negatively correlated with PANSS scores. A significant associations were also noted between the SLOF scores vs. PANSS Positive (*R* = −0.345, p \< 0.01) and Negative (*R* = −0.690, p \< 0.001) subscale scores.Table 2Correlations between scores of clinical measures (Pearson\'s *R*).Table 2SLOFSFSBACSUPSA-BBCISPANSSSLOF―.557 [⁎⁎](#tf0010){ref-type="table-fn"}.564 [⁎⁎](#tf0010){ref-type="table-fn"}.654 [⁎⁎](#tf0010){ref-type="table-fn"}.300 [⁎](#tf0005){ref-type="table-fn"}−.591 [⁎⁎](#tf0010){ref-type="table-fn"}SFS―.282 [⁎](#tf0005){ref-type="table-fn"}.342 [⁎⁎](#tf0010){ref-type="table-fn"}.171−.269 [⁎](#tf0005){ref-type="table-fn"}BACS―.738 [⁎⁎](#tf0010){ref-type="table-fn"}.354 [⁎⁎](#tf0010){ref-type="table-fn"}−.532 [⁎⁎](#tf0010){ref-type="table-fn"}UPSA-B―.267 [⁎](#tf0005){ref-type="table-fn"}−.607 [⁎⁎](#tf0010){ref-type="table-fn"}BCIS―−.176[^1][^2][^3][^4][^5][^6][^7][^8]

Further analysis, with z-transformation of correlation coefficients, indicated that the correlation between performance on the UPSA-B and SLOF scores was significantly more robust compared to the correlation between performance on the UPSA-B and SFS scores (z = 2.30, p \< 0.05). Similarly, the correlation between scores on the BACS and SLOF tended to be more robust than that between the BACS and SFS (Z = 1.89, P = 0.059).

Importantly, while the correlation between scores on the BCIS and SLOF reached significance, it was not so between scores on the BCIS and SFS ([Table 2](#t0010){ref-type="table"}, [Fig. 1](#f0005){ref-type="fig"}).Fig. 1Correlations between cognitive insight, measured by the Beck Cognitive Insight Scale (BCIS) vs. social function, measured by the Specific Levels of Functioning Scale (SLOF) or Social Function Scale for the MATRICS-PASS (SFS).Fig. 1

4. Discussion {#s0095}
=============

The results of this study suggest the validity of the SLOF Japanese version in terms of the relationship with SFS scores, another social function measure, as well as scores on the BACS (neuro-cognition) and UPSA-B (functional capacity), in patients with schizophrenia. Its internal consistency was found to be acceptable. Importantly, we have provided the first data indicating a positive correlation between cognitive insight and real-world outcomes, as measured by the SLOF.

The SLOF (English version) is recommended as one of the "real-world functional outcomes" measures ([@bb0015], [@bb0115], [@bb0120], [@bb0125], [@bb0130]), which has been shown to be closely linked to cognitive function and capacity of daily activity ([@bb0045]). The significant correlations with scores on the SFS \[another of the recommended real-world outcome measures ([@bb0070])\], UPSA-B, and BACS in the current study indicate convergent validity of the SLOF Japanese version. Specifically, the association with SFS scores suggest that the SLOF is useful as a measure of social function, or real-world functional outcomes. Further, the ability of the SLOF to predict scores on the UPSA-B and BACS, reported here, is consistent with results in the VALERO Study ([@bb0045]) with a similar set of performance-based measures, e.g. UPSA-B and MCCB. In fact, cognitive function evaluated by the BACS used here has been shown to correlate with performance on the MCCB Japanese version ([@bb0050]).

There was a difference in the degree of association with the performance-based measures (UPSA-B, BACS) between the SLOF and SFS ([Fig. 1](#f0005){ref-type="fig"}). The more robust associations for the SLOF can be explained by the fact that it was objectively rated (interview-based) while patients self-reported for the SFS. These results are similar to previous observations ([@bb0015]) that observer-, but not self-rated functional status was correlated with performance on the MCCB and UPSA-B in patients with schizophrenia, although our data indicate weak, but significant correlations between SFS scores vs. performances on the UPSA-B and BACS.

To our knowledge, the present study is the first to report a significant relationship between social function, measured by the SLOF, and cognitive insight, assessed by the BCIS. So far, several studies have sought to relate meta-cognition and cognitive function (neuropsychological performance) or functional capacity in subjects with schizophrenia. Thus, [@bb0080] observed positive correlations between "mastery", an ability to work through one\'s representativeness/mental states, as evaluated by the Metacognition Assessment Scale, and cognitive function, e.g. attention/information processing, learning memory, and executive function. The same group of investigators ([@bb0075]) also found this aspect of meta-cognition predicted performance on the UPSA (Comprehensive Planning domain). The positive correlation between SLOF and BCIS scores, observed in the present study, indicates the association between some types of meta-cognition and functional outcomes in patients with schizophrenia.

The positive relationship between cognitive insight and social function evaluated by the SLOF (interviewer-rated), but not SFS (self-reported) is consistent with the observation that ratings with the former scale were more strongly associated with performances on objective functional measures (i.e. BACS and UPSA-B). This finding also point to the usefulness of objective ratings of social function measures, as has been suggested ([@bb0015]).

The negative correlations between SLOF scores vs. scores on the PANSS (Total and Positive and Negative subscales) indicate the severity of psychotic symptoms affect social function. So far, the associations between positive ([@bb0020]) and negative ([@bb0110], [@bb0130]) symptoms vs. SLOF scores have been reported. Our findings are consistent with these previous observations, and provide additional evidence that overall psychiatric status, including positive symptoms, may be related to real-world functional outcomes in patients with schizophrenia.

The limitations of this study include the relatively small number of subjects and the cross-sectional nature. For example, it may be worthwhile to see if meta-cognition would be a determinant of long-term functional outcomes in individuals with schizophrenia-spectrum disorders.

In summary, the results of this study suggest that the SLOF Japanese version provides a measure of social consequences in patients with schizophrenia, indicating universality of this real-world functional outcomes scale. Importantly, we have provided the first evidence for a relationship between cognitive insight and social function evaluated by the SLOF. This finding is consistent with the observation that scores on this social outcome scale were considerably associated with performances on objective functional measures (BACS, UPSA-B).
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[^1]: BACS, Brief Assessment of Cognition in Schizophrenia.

[^2]: BCIS, Beck Cognitive Insight Scale.

[^3]: PANSS, Positive and Negative Syndrome Scale.

[^4]: SFS, Social Functioning Scale.

[^5]: SLOF, Social Functioning Scale.

[^6]: UPSA-B, UCSD Performance-based Skills Assessment-Brief.

[^7]: *p* \< 0.1.

[^8]: *p* \< 0.01.
